Peptide news
A curated feed of regulatory, scientific, industry and cultural developments. Each item links out to its original source — we summarise, we don’t republish.
- Regulatory
FDA advisory committee to review BPC-157, KPV, TB-500 and MOTS-c
The FDA's Pharmacy Compounding Advisory Committee is scheduled to weigh whether several popular peptides should remain available through compounding pharmacies.
- Culture
Why 'anti-aging' peptide shots are trending
A feature on the social-media-driven popularity of anti-aging peptide injections among celebrities — and what the science actually shows.
- Regulatory
BPC-157 removed from the FDA's restricted Category 2 list
BPC-157 entered a 'transitional' state — no longer barred from compounding, but still not an FDA-approved drug, pending a bulk-substances review.
- Regulatory
Wellness world eager for RFK Jr.'s move on peptides
Reporting on the policy push to widen consumer access to injectable peptides through compounding pharmacies, and the safety debate around it.
- Science
The Peptide Craze
Cardiologist Eric Topol examines the surge of interest in peptides and what the underlying evidence does and doesn't support.
- Regulatory
RFK Jr. signals ~14 peptides moving toward Category 1
Speaking on the Joe Rogan Experience, the HHS Secretary said he expected the FDA to reclassify about 14 injectable peptides to widen access from 'ethical suppliers'.
- Science
Influencers are promoting peptides — what does the science say?
A look at the gap between online enthusiasm for muscle-growth and longevity peptides and the thin state of human clinical evidence.
- Science
A closer look at unapproved peptide injections promoted by influencers
Coverage of the rise of unapproved peptide injections marketed by influencers and celebrities, and the regulatory questions they raise.
- Culture
Derrick Lewis says the UFC 'provided me with some great peptides'
The UFC heavyweight's comments drew a clarification from the promotion, which says it does not supply banned peptides.
- Industry
Peptide therapeutics market forecast for 2026
Market analysts project continued double-digit growth for the broad peptide-therapeutics category, though estimates vary widely by methodology.
- Science
The trend of unproven peptides spreading through influencers
An examination of how unregulated peptides have spread through wellness and fitness influencer culture.
- Regulatory
FDA removes five peptides from Category 2
An earlier loosening: AOD-9604, CJC-1295, Ipamorelin acetate, Thymosin Alpha-1 and Selank acetate were removed from the restricted compounding list (still not approved drugs).
12 items · summaries are neutral and link to the original reporting.